Table 2 |
||||||
|
Pharmacokinetic parameters |
||||||
|
Parameter analyzed |
Sequence |
Treatment |
Mean |
SD |
CV (%) |
Geometric mean |
|
|
||||||
|
AUC0-t(last) (μg/ml*h) |
AE/EA |
Nurofen® |
117.00 |
31.94 |
27.3 |
113.4 |
|
Eudorlin® |
119.79 |
29.04 |
24.2 |
116.6 |
||
|
EB/BE |
Migränin® |
115.21 |
21.83 |
19.0 |
113.1 |
|
|
Eudorlin® |
115.84 |
22.73 |
19.6 |
113.7 |
||
|
|
||||||
|
AUC0-∞ (μg/ml*h) |
AE/EA |
Nurofen® |
117.38 |
32.01 |
27.3 |
113.8 |
|
Eudorlin® |
120.15 |
29.07 |
24.2 |
117.0 |
||
|
EB/BE |
Migränin® |
115.57 |
21.84 |
18.9 |
113.5 |
|
|
Eudorlin® |
116.22 |
22.73 |
19.6 |
114.1 |
||
|
|
||||||
|
Cmax (μg/ml) |
AE/EA |
Nurofen® |
32.92 |
8.29 |
25.2 |
31.83 |
|
Eudorlin® |
36.62 |
6.16 |
16.8 |
36.11 |
||
|
EB/BE |
Migränin® |
30.87 |
6.31 |
20.4 |
30.25 |
|
|
Eudorlin® |
35.94 |
6.30 |
17.5 |
35.41 |
||
|
|
||||||
|
t1/2 (h) |
AE/EA |
Nurofen® |
2.52 |
0.44 |
17.6 |
2.495 |
|
Eudorlin® |
2.55 |
0.42 |
16.6 |
2.522 |
||
|
EB/BE |
Migränin® |
2.50 |
0.33 |
13.1 |
2.478 |
|
|
Eudorlin® |
2.66 |
0.79 |
29.8 |
2.583 |
||
|
|
||||||
|
|
||||||
|
Mean |
SD |
CV |
Median |
|||
|
|
||||||
|
tmax (h) |
AE/EA |
Nurofen® |
1.82 |
1.05 |
57.9 |
1.50 |
|
Eudorlin® |
1.14 |
0.67 |
59.1 |
1.00 |
||
|
EB/BE |
Migränin® |
1.78 |
0.97 |
54.5 |
1.75 |
|
|
Eudorlin® |
1.13 |
0.80 |
71.1 |
0.75 |
||
|
|
||||||
|
Pharmacokinetic data by treatment pair and treatment (Pharmacokinetic population; N = 60). "A" refers to Nurofen® forte, "B" refers to Migränin® and "E" refers to Eudorlin® extra. SD: standard deviation, CV: coefficient of variation. |
||||||
|
Bramlage and Goldis BMC Pharmacology 2008 8:18 doi:10.1186/1471-2210-8-18 |
||||||
